Business Context and Reporting Period
Company: Metavia Inc. (MTVA)
Filing Type: Form 8-K (Current Report)
Date: June 8, 2026
Context: The filing discloses late-breaking data presented at the American Diabetes Association (ADA) 2026 Scientific Sessions regarding the Company's obesity and metabolic disease portfolio. The report focuses on clinical results for DA-1726 and preclinical data for vanoglipel (DA-1241).
Key Financial Metrics
This Form 8-K is a disclosure of scientific and clinical developments. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any financial indicators.
Material Changes and Clinical Data
DA-1726 (Phase 1 Clinical Trial)
- Study Design: Randomized, double-blind, placebo-controlled Phase 1 multiple ascending dose study in obese adults.
- Safety: The 48 mg cohort was well tolerated with mild-to-moderate, transient gastrointestinal adverse events. No treatment-related discontinuations or serious adverse events occurred.
- Efficacy (Weight Loss):
- 6.1% reduction in body weight at Day 26 (p<0.05 vs placebo).
- 9.1% reduction in body weight at Day 54.
- No evidence of plateau through Week 8.
- Efficacy (Waist Circumference): Reduced by 5.8 cm at Day 22 and 9.8 cm at Day 54 (p<0.05 vs placebo).
- Efficacy (BMI): Reduced by 2.3 kg/m² at Day 22 and 3.4 kg/m² at Day 54.
Vanoglipel (DA-1241) (Preclinical Studies)
- Combination with Resmetirom (MASH Model):
- 23.6% reduction in body weight versus control (p<0.05).
- 43.5% reduction in endpoint fat mass and 42.1% reduction in epididymal fat weight.
- 83.5% reduction in ALT levels.
- Significant improvements in hepatic lipid accumulation, inflammation, and fibrosis biomarkers.
- Combination with Metformin (T2D/Obesity Model):
- 16.3% reduction in body weight versus control (p<0.05), compared to ~4% for monotherapies.
- 28.7% reduction in non-fasting glucose and 22.7% reduction in fasting glucose versus control.
- 3.6 g decrease in fat mass (-25.6% vs baseline).
- 6.4-fold increase in total GLP-1 and 1.5-fold increase in peptide YY (PYY) levels.
Guidance, Outlook, and Risks
Outlook: The Company states that the clinically meaningful, statistically significant body weight reductions for DA-1726 support continued development for obesity. The preclinical data for vanoglipel represents the first demonstration of therapeutic potential for combined targeting of GPR119 and thyroid hormone receptor beta (THRβ) for MASH.
Risks and Contingencies: The filing includes standard disclaimers that information in the press release is not "filed" under Section 18 of the Exchange Act and is not incorporated by reference except as expressly set forth. No specific financial risks or contingencies are detailed in this report.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for complete statistical tables and study limitations.
- Confirm the timeline for the next Phase 1 or Phase 2 clinical trial initiation for DA-1726.
- Assess the regulatory pathway and IND status for vanoglipel combination therapies in humans.
- Review the Company's cash runway and capital requirements to fund the continued development of these assets, as this 8-K contains no financial data.
- Monitor for any updates on the safety profile of DA-1726 beyond the 48 mg cohort.